Methicillin-resistant Staphylococcus aureus bacteremia at a university hospital in Japan

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Masaaki IsobeKazunori Tomono

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has become a leading cause of infections in hospitals, and mortality from MRSA bacteremia is high. In this study, we assessed the clinical characteristics and optimum management of 115 patients with MRSA bacteremia who were admitted to Osaka University Hospital between January 2006 and December 2010. Sixty-nine of the patients survived and 46 died of heart failure or renal failure. The nonsurvivors had reduced levels of platelets and albumin, and increased aspartate aminotransferase, total bilirubin, blood urea nitrogen, and creatinine levels. Other causes of death included sepsis, septic shock plus respiratory failure, disseminated intravascular coagulation, and unknown causes. However, a significant number of those whose infections were catheter-derived survived. Nonsurvivors were more often administered catecholamines and consultation with an infection-control team (ICT) was significantly associated with improved survival. Patients about whom the ICT were consulted were administered significantly more additional anti-MRSA drugs, for example trimethoprim-sulfamethoxazole, clindamycin, and gentamycin, than patients who were not the subject of consultation, although trough valu...Continue Reading

References

Dec 10, 1998·Journal of Internal Medicine·L LeiboviciS D Pitlik
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Aug 31, 2006·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Shunji TakakuraSatoshi Ichiyama
Feb 24, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J GómezM Valdés
May 23, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John F Mohr, Barbara E Murray
Sep 19, 2007·International Journal of Antimicrobial Agents·Ian M Gould
May 20, 2008·International Journal of Antimicrobial Agents·Ian M Gould
Jan 27, 2009·Intensive Care Medicine·Joana SilvestreH Sabino
Jun 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Leonard A MermelDavid K Warren
Jan 11, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuHenry F Chambers

❮ Previous
Next ❯

Citations

Apr 16, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Norihito KakuShigeru Kohno
Feb 24, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anthony D BaiAndrew M Morris
Apr 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eric WenzlerKarri A Bauer
May 8, 2020·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Etsuko Uejima
Sep 26, 2019·Current Pharmaceutical Design·Vivek K YadavSunil K Singh
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joshua C EbyHeather L Cox
May 29, 2015·Clinical Microbiology Reviews·Steven Y C TongVance G Fowler

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

The British Journal of General Practice : the Journal of the Royal College of General Practitioners
Tarique Khan, Amanda Beaumont
Annals of Emergency Medicine
Gregory J Moran, David A Talan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
James R Johnson
© 2021 Meta ULC. All rights reserved